We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
+$100M
Cap. Flow %
2.31%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Miscellaneous 3.74%
3 Financials 0.54%
4 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DNAB
76
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.94M 0.04%
200,000
– –
2021 Q2
4 quarters
DNAD
77
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.94M 0.04%
200,000
– –
2021 Q2
4 quarters
SCYX icon
78
SCYNEXIS
SCYX
$36.5M
$1.78M 0.04%
119,941
+51,936
+76% +$1,000K
2020 Q4
6 quarters
WGS icon
79
GeneDx Holdings
WGS
$1.9B
$1.2M 0.03%
28,788
– –
2021 Q1
5 quarters
SNCE
80
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$864K 0.02%
21,500
– –
2020 Q4
6 quarters
NUVB.WS icon
81
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$28K ﹤0.01%
99,999
– –
2021 Q1
5 quarters
MSACW
82
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$10K ﹤0.01%
57,770
– –
2021 Q2
4 quarters
ACET icon
83
Adicet Bio
ACET
$42.8M
– –
-195,000
Closed -$62.3M –
AXSM icon
84
Axsome Therapeutics
AXSM
$8.23B
– –
-711,000
Closed -$29.4M –
BAX icon
85
Baxter International
BAX
$13.1B
– –
-1,915,500
Closed -$149M –
BHC icon
86
Bausch Health
BHC
$2.36B
– –
-1,694,700
Closed -$38.7M –
BPMC icon
87
DELISTED
Blueprint Medicines
BPMC
– –
-291,184
Closed -$18.6M –
EW icon
88
Edwards Lifesciences
EW
$49.9B
– –
-440,000
Closed -$51.8M –
LKFT icon
89
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.96B
– –
-215,000
Closed -$13.3M –
INSM icon
90
Insmed
INSM
$21B
– –
-1,354,539
Closed -$31.8M –
ISRG icon
91
Intuitive Surgical
ISRG
$151B
– –
-325,000
Closed -$98M –
MLTX icon
92
MoonLake Immunotherapeutics
MLTX
$813M
– –
-400,000
Closed -$4.44M –
MRK icon
93
Merck
MRK
$360B
– –
-2,370,000
Closed -$194M –
PEN icon
94
Penumbra
PEN
$12.6B
– –
-104,000
Closed -$23.1M –
RCUS icon
95
Arcus Biosciences
RCUS
$2.82B
– –
-912,000
Closed -$28.8M –
SNTI icon
96
Senti Biosciences Holdings
SNTI
$7M
– –
-50,000
Closed -$4.93M –
VRDN icon
97
Viridian Therapeutics
VRDN
$2.16B
– –
-1,040,000
Closed -$19.2M –
XNTK icon
98
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.91B
– –
-3,300,000
Closed -$297M –
GRTS icon
99
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-560,000
Closed -$2.31M –
MRTX
100
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-1,393,000
Closed -$115M –
1 2 3
4
5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management's Q2 2022 filing shows 10 new, 31 increased, 13 reduced and 20 closed positions. Its largest new stake was Eli Lilly: 610,000 shares worth $198M. The largest sale was Merck, an estimated $194M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.